Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas

NCT03749187 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03749187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03749187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 3, 2019
Completion date
July 30, 2029
Enrollment
78 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, idh1 gene mutation, idh2 gene mutation, low grade glioma, malignant glioma, recurrent glioblastoma, recurrent who grade ii glioma, recurrent who grade iii glioma, who grade ii glioma, who grade iii glioma